比较脂质体阿霉素与普通阿霉素对淋巴瘤患者的临床疗效

Clinical effect of liposomal doxorubicin compared with adriamycin in the treatment of lymphoma

目的探讨脂质体阿霉素对比普通阿霉素治疗方案对淋巴瘤患者临床疗效及安全性。方法选取2012年1月至2014年1月间在惠州市第一人民医院接受治疗的非霍奇金淋巴瘤(NHL)患者42例,依据随机数字表法将患者分成观察组和对照组各21例,其中观察组采用脂质体阿霉素结合翘普(CHOP)方案进行化疗,对照组采用普通阿霉素结合CHOP方案进行化疗;观察患者近、远期治疗效果和不良反应情况。结果治疗后,观察组患者总有效率为66.66%,明显高于对照组的47.62%,差异有统计学意义(P<0.05);对照组患者在血小板减少、贫血、白细胞下降、心律失常和左室功能(LVEF)%降低方面的发生率均高于观察组,差异有统计学意义(P<0.05);观察组患者总生存期(OS)、无进展生存期(PFS)和平均生存时间略高于对照组,但差异无统计学意义(P>0.05)。结论脂质体阿霉素对NHL患者效果较好,患者不良反应比普通阿霉素更低,安全可靠。

Objective To study the clinical efficacy and safety of liposomal doxorubicin compared with adriamycin in the treatment of lymphoma. Methods A total of 42 non-Hodgkin′s lymphoma（NHL）patients who were treated at the First People′s Hospital of Huizhou City between January 2012 and January 2014 were selected. According to the random number table method,the patients were divided into observation group and control group,21 cases each. Among them,the observation group was treated with liposome doxorubicin combined with CHOP chemotherapy,and the control group was treated with common adriamycin combined with CHOP chemotherapy;the patient′s near and long-term treatment effects and adverse reactions were observed. Results After treatment,the total effective rate was 66.66% in the observation group,which was significantly higher than the 47.62% in the control group（P〈0.05）. The thrombocytopenia,anemia,leukopenia,arrhythmia,and left ventricular ejection fraction（LVEF）% incidence of reduction of control group was higher than that ofthe observation group. The difference was statistically significant（P〈0.05）. The overall survival（OS）,progress free survival（PFS） and mean survival time of the observation group were slightly higher than those of the control group,but the difference was not statistically significant（P〉0.05）. Conclusion The liposomal doxorubicin has a better effect on NHL patients. The adverse reactions of patients are lower than that of common adriamycin,which is safe and reliable.